Effect of Hemodialysis on Plasma Levels of Vascular Endothelial Markers

Abstract

Vascular endothelial cell dysfunction is linked to hemostatic abnormalities and accelerated atherosclerosis in patients receiving maintenance hemodialysis (HD). The relationships between pre-dialysis plasma levels of immunoreactive thrombomodulin, von Willebrand factor, tissue factor and its inhibitor were studied, and the effects of HD procedure on these endothelial markers were observed. All the markers were higher in 39 HD patients than in 15 healthy controls (p<0.0001). HD treatment resulted in a 50% increase in tissue factor pathway inhibitor (p<0.0001), but did not influence the other markers. This increment directly correlated with the post-dialysis decrease in diastolic (p=0.011) and mean arterial blood pressure (p=0.039), and the surface area of the dialysis membrane (p=0.007). There were no associations between the increase in tissue factor pathway inhibitor and the amount of fluid removed, dose of enoxaparin, or other HD-specific factors. In conclusion, HD is responsible for an increase in plasma tissue pathway factor inhibitor level. The release of tissue factor pathway inhibitor during HD is not only due to heparin injection but also to the contact between blood and artificial dialysis membrane, and to HD-activated hemodynamic forces.

Keywords

Arterial blood pressure Endothelium Dialysis membrane Tissue factor pathway inhibitor

References

1. Gris J-C , Branger B , Vecina F , et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994;46:807-807.

2. Pannier B , Guerin AP , Marchais SJ , et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 2000;5:1091-1091.

3. Stenvinkel P , Heimburger 0 , Lindholm B , et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-953.

4. Stenvinkel P.

Endothelial dysfunction and inflammation -is there a link?

Nephrol Dial Transplant 2001;16:1968-1968.

5. Borawski J , Naumnik B , Pawlak K , et al. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. Nephrol Dial Transplant 2001;16:787-787.

6. Borawski J , Naumnik B , Mysliwiec M. Increased soluble thrombomodulin does not always indicate endothelial injury. Clin Appl Thromb Hemost 2002;8:87-87.

7. Borawski J , Naumnik B , Pawlak K , et al. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: Associations with pre-dialysis blood pressure and acute phase response. Nephrol Dial Transplant 2001;16:1442-1442.

8. Kario K , Matsuo T , Matsuo M , et al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995;73:763-763.

9. Matsuo T , Koide M , Kario K , et al. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis 1997;27:163-163.

10.

10. Mayszko J , Malyszko JS , Mysliwiec M. TF and TFPI in CAPD and HD. Nephrol Dial Transplant 1998;13:2424-2424.

11.

11. Zwolifiska D , Medyfiska A , Szprynger K , et al. Serum concentration of IL-1, IL-6, TNF-Alpha and their soluble receptors in children on maintenance hemodialysis. Nephron 2000;86:441-441.

12.

12. Kario K , Matsuo T , Yamada T , et al. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994;71:275-275.

13.

13. Naumnik B , Borawski J , Myśliwiec M. Tissue factor (TF) and its inhibitor (TFPI) in hemodialyzed patients: Associations with viral hepatitis. Thromb Haemost 2001;(suppl on CD-ROM):CD3196-CD3196.

14.

14. Cella G , Vertolli U , Naso A , et al. Tissue factor pathway inhibitor (TFPI) activity in uremic patients during haemodialysis. Thromb Res 1996;81:671-671.

15.

15. Hansen JB , Sandset PM . Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy. Thromb Res 1998;91:177-177.

16.

16. Miyazaki H , Matsuoka H , Itabe H , et al. Hemodialysis impairs endothelial function via oxidative stress. Effects of vitamin E-coated dialyzer. Circulation 2000;101:1002-1002.

17.

17. Kosch M , Levers A , Barenbrock M , et al. Acute effects of haemodialysis on endothelial function and large artery elasticity. Nephrol Dial Transplant 2001;16:1663-1663.

18.

18. Savage T , Fabbian F , Giles M , et al. Interdialytic weight gain and 48-h blood pressure in haemodialysis patients. Nephrol Dial Transplant 1997;12:2308-2308.

19.

19. Nishimura M. Role of NO in hemodialysis hypotension. Int JArtif Organs 1999;22:789-789.

20.

20. Gimbrone MA, Jr. Endothelial dysfunction, hemodynamic forces and atherosclerosis. Thromb Haemost 1999;82:722-722.

21.

21. Blacher J , Pannier B , Guerin AP , et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32:570-570.

22.

22. Foley RN , Collins AJ , Herzog CA . Pre and post-dialysis blood pressure patterns and mortality in dialysis patients: The USRDS wave 3 & 4 study. J Am Soc Nephrol 2001;12:A1949-A1949.